Displaying One Session

Jazz Pharmaceuticals - Insight beyond Phase 3: does real-world evidence impact how we treat high-risk AML*? *High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC) (ID 147)

Time
08:45 - 09:45

What has Phase 3 data told us about increasing long-term remission in high-risk AML*? (ID 5147)

Do real-world studies confirm the Phase 3 data and how will they impact the management of high-risk AML*? (ID 5148)